Sign in
Knowstox

Fundamentals snapshot

Aclaris Therapeutics, Inc.

ACRS · NMS · Healthcare · Biotechnology

Current price

$3.60

52-week range

$1.74 - $6.60

Market cap

$529.92M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-9.70x Concerning

Net cash $89.71M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Aclaris Therapeutics, Inc.

Aclaris Therapeutics develops new medicines for immune system and inflammation problems, like skin conditions and breathing issues. Their main money source will eventually be selling these approved drugs, which matters because it shows if their research is paying off and can bring in profits. They are currently focused on testing these potential new treatments in human trials to see if they are safe and effective.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $22.00M FY2024 Q4 $-8.94M FY2025 Q1 $-13.10M FY2025 Q2 $-10.01M FY2025 Q3 $-10.96M FY2025 Q4 $-13.15M FY2026 Q1 $-18.16M FY2026 Q2 $-19.91M
Revenue $1.63M
Net income $-21.50M
Diluted EPS -0.15
Operating cash flow $-19.85M
Free cash flow $-19.91M
Revenue $2.00M
Net income $-19.82M
Diluted EPS -0.15
Operating cash flow $-18.15M
Free cash flow $-18.16M
Revenue $1.29M
Net income $-19.80M
Diluted EPS -0.16
Operating cash flow $-13.13M
Free cash flow $-13.15M
Revenue $3.30M
Net income $-14.61M
Diluted EPS -0.12
Operating cash flow $-10.93M
Free cash flow $-10.96M
Revenue $1.78M
Net income $-15.43M
Diluted EPS -0.13
Operating cash flow $-9.99M
Free cash flow $-10.01M
Revenue $1.46M
Net income $-15.09M
Diluted EPS -0.12
Operating cash flow $-13.06M
Free cash flow $-13.10M
Revenue $9.21M
Net income $-96.55M
Diluted EPS -1.21
Operating cash flow $-8.94M
Free cash flow $-8.94M
Revenue $4.35M
Net income $-7.59M
Diluted EPS -0.11
Operating cash flow $22.00M
Free cash flow $22.00M

Is it cheap or expensive?

Fair value — vs current price $3.60

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $89.7M - more cash than debt. Interest coverage -9.7x.

Net debt $-89.71M
Interest coverage -9.70x

Aclaris Therapeutics, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.

Healthy
Worse cushion Baseline Better cushion
ACRS BASELINE Aclaris Therapeutics, Inc.

Total debt $1.85M Interest coverage -9.70x This is the baseline the peer rows are being compared against.

-9.70x

What you should know

The case for and against ACRS

1 Reward 2 Risks

Rewards

  • Revenue grew 5.0% last year.

Risks

  • Operating margin compressed from -286.2% to -1469.5% over 3 years.
  • Return on equity was -59.1% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-4.57x
P/B
4.04x
P/S
64.47x
EV/EBITDA
-5.15x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
-1,469.5%
Net margin
0.0%
ROE
-59.1%
ROA
-29.0%

Health

Liquidity and balance-sheet strength

Debt / equity
0.01x
Current ratio
3.46x
Quick ratio
3.46x
Total debt
$1.85M
Total cash
$91.56M

Growth

How the business has been compounding

Revenue TTM
$8.22M
Revenue 5Y CAGR
3.7%
EPS TTM
-0.58
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-62.06M
Free CF TTM
$-47.22M
FCF margin
-574.6%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—